Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma

Cholangiocarcinoma Clinical Trial

Official title:

Exploratory Clinical Study of Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05697237
• Other study ID #: XJTU1AF2021LSK-368
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 2023
• Est. completion date: December 2024

Study information

• Verified date: December 2022
• Source: First Affiliated Hospital Xi'an Jiaotong University
• Contact: yangwei fan, phd
• Phone: +8615029078171
• Email: 1159950306[@]qq.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The incidence of cholangiocarcinoma is high, the radical resection rate is low, the postoperative recurrence is easy, the prognosis is poor.Gemcitabine combined with cisplatin (GC) is the standard first-line treatment for patients with advanced biliary carcinoma, and up to now there is no standard second-line treatment Commend.Carrilizumab was highly effective in previous studies,Its combined GEMOX protocol has been published in the "Guidelines for the Diagnosis and Treatment of Gallbladder Cancer (2019 Edition)" and the "China Clinical Oncology" The Society's (CSCO) Guidelines for the Diagnosis and Treatment of Biliary alignancies 2020 is recommended for the first-line treatment of advanced biliary cancers.Solfantinib is targeted at VEGFR1, 2, 3, FGFR1And CSF1R highly selective small molecule targeted therapy drugs. Data from a preliminary phase 2 clinical trial observed sofantinib therapy Survival benefits of cholangiocarcinoma patients in China.

Description:

In this study, carrilizumab combined with suvantinib in the second-line treatment of patients with advanced or metastatic cholangiocarcinoma with single arm, open, Exploratory clinical trials. The study plan enlists 60 patients with unresectable or recurrent disease confirmed by histopathology or cytology Or metastatic cholangiocarcinoma (including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, distal cholangiocarcinoma). Past acceptance of standard containing Systematic internal medicine anti-tumor therapy with gemcitabine regimen met the inclusion criteria of this study, and carrilizumab combined with cord was given Vantinib oral therapy. The specific treatment regimen was carrilizumab 200mg Q3W d1; Solventinib: 300mg, Orally, once a day, continuously. Treatment continues or until disease progression occurs or the patient becomes intolerant to the treatment regimen The efficacy was evaluated every 2 cycles. The main evaluation of carrilizumab combined with suvantinib in second-line treatment was advanced or Progression-free survival (PFS) in patients with metastatic cholangiocarcinoma.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: December 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Advanced inability to root was pathologically confirmed Patients with curatively resected or metastatic bile duct epithelial cell carcinoma;

2. had previously received systemic antitumor therapy with a chemotherapy regimen (including gemcitabine)

3. Age =18 and under 75

4. Predicted survival =3 months

5. ECOG score 0-1

6. Child-Pugh score < 8

7. There was at least one measurable tumor lesion with a long diameter =10 mm and a short diameter =15 mm on spiral CT,For general CT or physical examination, the maximum diameter must be =20mm

8. The results of liver and kidney function and blood routine examination within 1 week before enrollment were consistent with the following conditions:ANC=1.5×10^9/L,PLT=80×10^9/L,HGB=80g/L,Cr=1.5×ULN,TBIL=2.5×ULN,ALP=2.5×ULN, AST=2.5×ULN,ALT=2.5×ULN

9. Patients participate voluntarily and sign informed consent forms

Exclusion Criteria:

1. Known allergies to carrilizumab or solfantinib machine components

2. Patients with obstructive jaundice who could not reach the upper limit of TBIL=2.5 times of normal value after surgical intervention

3. Patients with biliary obstruction that may occur or worsen within 4 to 6 weeks

4. Patients with obvious coagulation mechanism disorder, active bleeding and bleeding tendency

5. History of other malignancies within 5 years (fully treated basal cell carcinoma of the skin, cervical cancer in situ)

6. Interstitial pneumonia or pulmonary fibrosis

7. Uncontrollable pleural effusion or ascites

8. Severe uncontrolled medical disease, acute infection, recent history of myocardial infarction (within 3 months)

9. Pregnant or lactating mothers who refused to take appropriate contraceptive measures during the course of the study;

10. The researchers determined that the patients were not suitable for this study

Related Conditions & MeSH terms

• Cholangiocarcinoma

Intervention

Drug:
• Carrelizumab
Carrelizumab 200mg/3 weeks
• Solfantinib
Solfantinib 300mg/d

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
First Affiliated Hospital Xi'an Jiaotong University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PFS	Progression Free Survival	6months
Secondary	ORR	Objective Response Rate	6months
Secondary	OS	Overall Survival	12months
Secondary	DCR	Disease control rate Disease control rate Disease control rate	6months